Science Featured on MSN28d
This Common Cancer Treatment Might Help Patients Stay Healthier for Longer
Understanding how to keep leukemia in remission for longer in older patients remains a significant challenge in cancer ...
News Medical5y
Azacitidine-Teva
If you are worried about using this medicine, speak to your doctor or pharmacist. Azacitidine-Teva contains the active ingredient azacitidine. Azacitidine-Teva is used to treat myelodysplastic ...
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Combination with mipletamig continues to outperform ...
ImCheck to Present Updated ICT01 Data with Unprecedented High Rates of Complete Remission in AML at the AACR Annual Meeting 2025
EST/21:30 CET– ImCheck Therapeutics announced today it will present updated results from its ongoing open-label, randomized ...
pharmaphorum2d
BMS preps filings for leukaemia maintenance therapy CC-486
Celgene’s pipeline has delivered another new drug filing for Bristol-Myers Squibb, thanks to positive results for oral azacitidine formulation CC-486 in the phase 3 QUAZAR AML-001 trial.
Zacks.com on MSN4mon
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
The phase III SELECT-MDS-1 study evaluated tamibarotene in combination with azacitidine, a chemotherapy, in newly diagnosed ...
Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment
Aptevo Therapeutics (NASDAQ:APVO) announced two additional frontline Acute Myeloid Leukemia (AML) patients have achieved ...